宫颈癌患者癌症治疗的不良反应
Adverse Effects of Cancer Treatment in Patients With Cervical Cancer.
作者信息
Palagudi Mahesh, Para Sneha, Golla Nagasree, Meduri Krishna Chaitanya, Duvvuri Sai Praneeth, Vityala Yethindra, Sajja Deepika Chowdary, Damineni Ujwala
机构信息
Department of General Medicine, P.E.S. Institute of Medical Sciences and Research, Kuppam, IND.
Department of General Medicine, Maheshwara Medical College and Hospital, Hyderabad, IND.
出版信息
Cureus. 2024 Feb 13;16(2):e54106. doi: 10.7759/cureus.54106. eCollection 2024 Feb.
BACKGROUND
In lower- to middle-income countries such as India, the literature on the adverse effects (AEs) of cancer treatment in patients with cervical cancer is very limited. This knowledge gap provides an opportunity to investigate and improve the quality of life for women with cervical cancer.
OBJECTIVE
The purpose of this study was to assess the AEs of various cancer treatment combinations in patients with cervical cancer.
METHODS
This observational, retrospective study analysed 1,030 women with cervical cancer, with a descriptive cross-sectional design, based on a review of medical records from patients who were followed up during the morbidity consultation conducted by a multidisciplinary team of doctors. The AEs of cancer treatment for women with cervical cancer were recorded in these medical records between October 14, 2019, and November 21, 2022, at 10 major public tertiary hospitals in India.
RESULTS
This study analysed 1,030 women with cervical cancer aged between 21 and 80 years (mean age: 48.8 ± 13.9 years; p=0.30). Patients between the ages of 36-50 years reported the most AEs (30.2%; 95% confidence interval (CI): 29.1-32.8) among other age groups. Combined radiation therapy and chemotherapy (CT) was the type of cancer treatment in which there were more AEs, presenting in 56.0% (95% CI: 55-60.1) of patients. Adverse effects associated with the gastrointestinal system were observed in the majority (92.5%, 95% CI: 90.2-96.9) of cervical cancer patients.
CONCLUSION
Exposure to different cancer treatments, particularly combination therapy, induces AEs in patients during and after cervical cancer treatment.
背景
在印度等中低收入国家，关于宫颈癌患者癌症治疗不良反应（AE）的文献非常有限。这一知识空白为研究和改善宫颈癌女性的生活质量提供了契机。
目的
本研究旨在评估宫颈癌患者各种癌症治疗组合的不良反应。
方法
本观察性回顾性研究采用描述性横断面设计，分析了1030例宫颈癌女性患者，这些患者来自多学科医生团队在发病咨询期间进行随访的患者病历回顾。2019年10月14日至2022年11月21日期间，在印度10家主要的公立三级医院，这些病历记录了宫颈癌女性患者癌症治疗的不良反应。
结果
本研究分析了1030例年龄在21至80岁之间的宫颈癌女性患者（平均年龄：48.8±13.9岁；p = 0.30）。36至50岁的患者在其他年龄组中报告的不良反应最多（30.2%；95%置信区间（CI）：29.1 - 32.8）。联合放疗和化疗（CT）是不良反应较多的癌症治疗类型，56.0%（95% CI：55 - 60.1）的患者出现该情况。大多数（92.5%，95% CI：90.2 - 96.9）宫颈癌患者观察到与胃肠道系统相关的不良反应。
结论
接触不同的癌症治疗，尤其是联合治疗，会在宫颈癌治疗期间和治疗后诱发患者出现不良反应。
Zotero 插件